Understanding how different types of immune cells behave in acute respiratory distress syndrome (ARDS)
Official title: Alveolar macrophage subset ontogeny and differentiation during ARDS
Funded at University of Washington · NIH-11128438 · Data updated 2026-11-12
This study is looking at how certain immune cells in the lungs, called alveolar macrophages, behave during acute respiratory distress syndrome (ARDS) to see if they can help or hurt patients, with the hope of finding new ways to treat this serious lung condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | June 30, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $707,105 |
| NIH project number | 5R01HL169265-02 |
| Project ID | NIH-11128438 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acute respiratory distress syndrome.
✕Less likely to help
Patients with chronic respiratory conditions or those not experiencing acute respiratory distress may not benefit from this research.
What this research studies
This research investigates the role of alveolar macrophages, a type of immune cell, in acute respiratory distress syndrome (ARDS), a serious lung condition. The study focuses on how these cells develop and differentiate, particularly during lung injury, and aims to identify specific subsets of these cells that may influence patient outcomes. By using animal models, researchers will explore how these immune cells can either worsen or improve the condition, providing insights that could lead to new treatments for ARDS. The findings could help in understanding the mechanisms behind ARDS and potentially guide the development of therapies targeting these immune cells.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve outcomes for patients suffering from ARDS.
How similar studies have gone: Previous research has shown promise in targeting immune cells for improving outcomes in ARDS, indicating that this approach may be viable.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Morrell, Eric Douglas — University of Washington
- Study coordinator: Morrell, Eric Douglas
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.